09966 ALPHAMAB-B
- 5.200
- -0.030-0.57%
ALPHAMAB-B News
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Corning Jerry will first announce Chinese clinical study data on JSKN003 treatment of HER2-expressing solid tumors at the 2024 ASCO Annual Meeting
SUZHOU, May 6, 2024/PRNewswire/ -- Corning Jerry Biopharmaceuticals (stock code: 9966.HK) announced that the company will first announce the Chinese clinical study data (study number: JSKN003-102) of the HER2 double antagonist conjugate drug JSKN003 to treat HER2-expressing solid tumors at the 2024 American Society of Clinical Oncology (ASCO) annual meeting. This year's ASCO Annual Meeting will be held in Chicago, USA from May 31 to June 4, 2024, local time. Topic: Safety and pharmacokinetics of JSKN003 in patients with advanced solid tumors
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
Alphamab Oncology's 2023 Loss Narrows as Revenue Rises
Alphamab Oncology's (HKG:9966) loss narrowed to 210.6 million yuan, or 0.22 yuan per share, in 2023 from 325.7 million yuan, or 0.35 yuan per share, in 2022, according to the company's annual report f
康寧傑瑞製藥-B：2023年報
Corning Jerry Pharmaceutical-B (09966.HK) grants 1.18 million share options
Glonghui, April 23 | Corning Jerry Pharmaceutical-B (09966.HK) announced that on April 23, 2024, according to the initial public offering after-sales share option plan, the company has decided to grant 1.18 million share options to four eligible participants (that is, employees of the Group), at an exercise price of HK$4.350 per share. Under the restricted share award scheme, the company has decided to award a total of 130,000 award shares to two eligible participants (i.e. employees of the Group). The purpose of granting share options and rewarding shares is to: (i) recognize the share option grantor and reward the grantee's contributions to the Group; (i
Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting
Alphamab Oncology (HKG:9966) said it presented the phase-I clinical trial results of its cancer drug during a poster session at the American Association for Cancer Research annual meeting, according t
HER2 dual antibody ADC drug JSKN003 Australian Phase I clinical study data unveiled at 2024 AACR annual meeting
The findings of JSKN003 during the dose escalation period (Ia) were reported at this AACR conference. The treatment of advanced HER2 expression/metastatic solid tumors with JSKN003 showed encouraging efficacy signals, with an ORR of 100% in patients with HER2-positive breast cancer. The tolerability and safety are good, DLT has not occurred, and MTD has not been achieved. Suzhou, China, April 10, 2024 /PRNewswire/ -- Corning Jerry Biopharmaceuticals (stock code: 9966.HK) announced the company at the 2024 American Association for Cancer Research Annual Meeting (AACR 2024)
Featured announcements | Shunyu Optics mobile phone lens shipments increased by more than 30%; China Life Insurance's original premium revenue increased by 3.2%
Hang Seng Bank: It plans to repurchase no more than HK$3 billion of shares. The automatic share repurchase plan will run from April 10, 2024 to September 9, 2024; Shandong Gold: A wholly-owned subsidiary in Hong Kong plans to apply for a revolving loan of US$30 million from Bank of Communications (Hong Kong).
Corning Jerry Pharmaceutical-B (09966.HK): The latest results of the Phase I clinical study of JSKN003 for the treatment of advanced solid tumors with advanced HER2 expression presented at the 2024 AACR Annual Meeting
Gelonghui, April 10, 丨 Corning Jerry Pharmaceutical-B (09966.HK) announced that the results of the JSKN003 Phase I clinical study (study number: JSKN003-101) (“JSKN003-101”) for the treatment of patients with advanced/metastatic solid tumors (poster board number: 7; abstract number: CT179) were presented during the poster presentation period at the 2024 AACR Annual Conference held from April 5 to April 10, 2024.
Alphamab Oncology Unit Renews Service Provision Contract, Annual Limits
Alphamab Oncology (HKG:9966) unit Jiangsu Alphamab Biopharmaceuticals has renewed an agreement to continue providing certain services to Suzhou Alphamab from April 2 to Dec. 31, 2025, a Tuesday filin
Corning Jerry Announces 2023 Annual Results and Recent Business Developments
SUZHOU, March 29, 2024/PRNewswire/ -- Corning Jerry Biopharmaceuticals (stock code: 9966.HK) announced its full year results and recent business developments for the year ended December 31, 2023. Dr. Xu Ting, Chairman and President of Corning Jerry, said, “In 2023, Corning Jerry will continue to target clinical needs and insist on differentiated innovation. The company already has one marketed product and three products in the clinical phase of registration. We will continue to improve our antibody engineering platform and develop safe and effective new anti-tumor drugs. At the same time, we will accelerate clinical development, product launch, and international cooperation.”
Corning Jerry Pharmaceutical-B (09966) announced its 2023 annual results, with a loss of 211 million yuan during the year, a year-on-year decrease of 35.35%
Corning Jerry Pharmaceutical-B (09966) announced its 2023 annual results, with revenue of RMB 219 million, an increase over the previous year...
ALPHAMAB-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Intraday quick overview | The three major indices rose sharply, the Keji Index rose more than 2%, Bilibili rose nearly 8%, and JD and Meituan rose more than 5%
Biotech stocks rose, with Yao Ming Biotech up more than 6%, Genting Xinyao by more than 5%, Kingsray Biotech by more than 4%, and BeiGene Shenzhou by nearly 2%; Apple concept stocks generally rose, Ruisheng Technology and Gaowei Electronics by about 5%, and Shunyu Optics and Qiutai Technology by about 2%.
Corning Jerry's subcutaneous drug JSKN033 completes first patient administration in Australia
SUZHOU, March 26, 2024/PRNewswire/ -- Corning Jerry Biopharmaceuticals (stock code: 9966.HK) announced that a clinical study for the treatment of advanced HER2 expression or metastatic solid tumors with advanced HER2 expression or metastatic solid tumors (study number JSKN033-101) has completed the first patient administration in Australia. Clinical research results have shown that ADC combined immunotherapy can improve treatment efficacy and significantly prolong survival. However, combination treatment increased the patient's infusion time and hospitalization time, and the occurrence of infusion reactions
The full study results of kn046 combined with chemotherapy for first-line treatment of metastatic non-small cell lung cancer were published in Cell sub-journal
SUZHOU, March 22, 2024/PRNewswire/ -- Corning Jerry Biopharmaceuticals (stock code: 9966.HK) announced that the full results of the Phase II clinical study (KN046-202) of PD-L1/CTLA-4 combined with KN046 combined chemotherapy for first-line treatment of metastatic non-small cell lung cancer were published in Cell Reports Medicine (IF:14.3). Professor Zhang Li from Sun Yat-sen University Cancer Center is the corresponding author of this article, and Professor Zhao Yuanyuan is the first author. Corresponding author: Professor Zhang Li First Author: Zhao Yuanyuan
Corning Jerry Pharmaceutical-B (09966.HK) plans to hold a board meeting on March 28 to consider and approve annual results
Glonghui March 18 | Corning Jerry Pharmaceutical-B (09966.HK) announced that a board meeting will be held on March 28, 2024 (Thursday) to consider and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to deal with other matters.
ALPHAMAB-B: DATE OF BOARD MEETING
Corning Jerry will present clinical study data on JSKN003 treatment of HER2-expressing solid tumors at AACR 2024
SUZHOU, March 14, 2024/PRNewswire/ -- Corning Jerry Biopharmaceuticals (stock code: 9966.HK) announced that the Phase I clinical study data (study number: JSKN003-101) of the HER2 double antibody conjugate drug JSKN003 for the treatment of advanced HER2-expressing solid tumors in Australia (study number:) was selected for the 2024 American Association for Cancer Research Annual Meeting (AACR 2024) and will be announced in the form of a poster. The AACR Annual Conference is one of the oldest and largest scientific conferences in the world. It focuses on all aspects of high-quality and innovative oncology research and focuses on cancer leaders
Analysis
Price Target
No Data
